Release Summary

Catabasis will present new MRI data from the open-label extension MoveDMD trial of edasalonexent (CAT-1004) for the treatment of DMD at the American Academy of Neurology 70th Annual Meeting.

Catabasis Pharmaceuticals, Inc.